

filed 8/09/02 (2)

Express Mail No. EK655899240

Form PTO-1449 (Rev. 2-97 by App.)

U.S. Department of Commerce Att'y Docket No. Patent and Trademark Office

Serial No. Applicants: INFORMATION DISCLOSURE CITATION

Filing Date Group Art Unit: 98M06 Woltering

Eugene A. Woltering et al. May 25, 2001

Page 1 06

U.S. PATENT DOCUMENTS

Document No.

File Date 11/19/98

09/196,259 which is now Cov. et al.

(use Several Sheets if Necessary)

FOREIGN PATENT DOCUMENTS

Exam. Initial

1.09.04.

Document No.

Country

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

Gulec, S. et al., "A new in vitro angiogenesis assay with spatially intact human tumor architecture. The 3D tumor angiogenesis model (3DTAM) (preprint 2001)

Gulec, S. et al., "Anti-angiogenic treatment with somatostatin receptor-mediated in situ

radiation," American Surgeon (in press, 2001)

Gulec, S. et al., "Antitumor and antiangiogenic effects of somatostatin receptortargeted in situ radiation with 111In-DTPA-JIC 2DL," J. Surg. Res. vol. 97, pp. 131-137 (2001)

EXAMINER

V. Spun V. Afpermaa

1-08-04

DATE CONSIDERED 8-03-02

* EXAMINER:

Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw a line through the citation if not in conformance and not considered. Include copy of this form with next communication to applicant

filed \$126/02



U.S. Department of Commerce Att'y Docket No. Patent and Trademark Office Serial No.

Applicants:

Filing Date Group Art Unit: Page 1 of 1

98M06.1 Woltering 09/866,296

Eugene A. Woltering et al. May 25, 2001

LUS PATENT DOCUMENTS

1.08.04

Document No

Country

Class

Subcl.

ANCO SA SA SOTT ER DO SUMENTS A INCLUSIVO AURDO STRACTORIA PARTICIPADA

Gulec, S. et al., "A new in vitro angiogenesis assay with spatially intact human tumor architecture. The 3D tumor angiogenesis model (3DTAM)" (preprint 2001).

Gulec, S. et al., "Anti-angiogenic treatment with somatostatin receptor-mediated in situ radiation," American Surgeon (in press, 2001)

walkerswan in affections

EXAMINER

V. Shrama

INFORMATION DISCLOSURE CITATION

(use Several Sheets if Necessary)

DATE CONSIDERED 1-08-04

EXAMINER:

Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw a line through the citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

CERTIFICATE

I hereby certify that this Information Disclosure Citation and a copy of the three cited references are being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Box Non-Fee Amendment, Washington, D.C. 20231 on August 20-2002.

> John H. Runnels Registration No. 33,451

August 20, 2002

filed 4/04/03 on 2/03/02 Page 1 of 1

Form PTO-1449 (Rev. 2-97 by App.)

U.S. Department of Commerce Patent and Trademark Office

Applicants: Serial No.

Eugene A. Woltering et al. 09/866.296

May 25, 2001 Filing Date:

98M06.1 Woltering Att'y Docket No. Examiner: Afremova, Vera

Group Art Unit: 1651

INFORMATION DISCLOSURE CITATION

(use Several Sheets if Necessary)

U.S. PATENT DOCUMENTS

Date Name Class Subcl Document No. 530 11/98 311 6.465.613 10/02 Coy et al. Parish et al. 435 10/96 5.976,782 11/99

FOREIGN PATENT DOCUMENTS

Exam. Initial Document No.

Country

Class

Subcl.

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

Gulec, S. et al., "Antitumor and Antiangiogenic Effects of Somatostatin Receptor--Targeted in Situ Radiation with 111 In-DTPA-JIC 2DL," J. Surg. Res., vol. 97, pp.

313-137 (2001)

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw a line through the citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

CERTIFICATE

I hereby certify that this Information Disclosure Citation, the accompanying Information Disclosure Statement, and copies of the three cited references are being deposited with the United States Postal Service as first class mail in an envelope adressed to: Commissioner for Patents, Box RCE, Washington, D.C. 20231 on January 28, 2003.

Registration No. 33,451

January 28, 2003